Identifying suitable animal models with similar physiology to humans remains an important step for cancer researchers seeking predictable preclinical results. Cambridge Healthtech Institute’s second annual Predictive Preclinical Models in Oncology conference (February 10-12, San Francisco) will feature effective in vitro and in vivo preclinical models for evaluating recently developed cancer therapeutics.
Key topics will include using tumor models in translational cancer research, optimizing and guaranteeing predictability of tumor models, models for cancer immunotherapy, and challenging cancer genomic heterogeneity. Speakers will include Frederic de Sauvage, vice president of Genentech, Jocelyn Holash, senior research investigator at Novartis, and David Gandara, professor of medicine at the University of California, Davis School of Medicine. Top sponsors include Thomson Reuters.
For more information, visit the conference website.